Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology, Metabolic & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CMKLR1 (ChemR23) GPCR drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Cell System | CMKLR1 Stable Cell Line (Lentivirus Transduced). Full-length GPCR surface expression. Sequence Verified. HEK293 Expressed. | View CMKLR1 Products |
| Gene Delivery | CMKLR1 Lentivirus Premade Particles. Full-length ORF for stable cell line construction. Purity >95%, Endotoxin <1EU/ug. | View CMKLR1 Products |
| Benchmark Ab | Anti-CMKLR1 Recombinant Antibody (Monoclonal). Sequence-defined positive control for binding and neutralization assays. | View CMKLR1 Products |
| Validator | CMKLR1 siRNA Set. For knockdown and specificity verification in cell-based assays. | View CMKLR1 Products |
| Ligand | RARRES2 (Chemerin) Recombinant Protein. Native ligand for binding and functional assays. High Purity (>95%), Endotoxin Controlled. HEK293 expressed, native glycosylation. | View RARRES2 Products |
| Related Target A | GPR1. Alternate chemerin receptor; essential for selectivity counter-screening and off-target profiling. | View GPR1 Products |
| Related Target B | CCRL2. Chemerin-presenting non-signaling receptor; synergistic pathway node in inflammation and gradient formation. | View CCRL2 Products |
| Related Target C | FPR2. Shared resolvin E1 signaling network for selectivity screening in pro-resolving pathways. | View FPR2 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation & Glycosylation Preservation | Full-length CMKLR1 delivered via Lentivirus for Stable Cell Line; preserves native folding and post-translational modifications. |
| Cross-species Preclinical Evaluation (Human/Mouse/Cyno) | Human / Mouse / Cyno ortholog receptor expression systems available with sequence-verified ORFs (NGS). |
| Subfamily Selectivity (GPR1 / CCRL2 / FPR2) | Homolog panel cell lines and proteins strictly verified by sequencing and mass spec for counter-screening. |
| Lack of Binding & Functional Controls | Clinical Benchmark Format Antibodies and Recombinant RARRES2 Ligand included as assay standards. |
| False Positives in Binding Screens | CMKLR1 siRNA included for target-specificity validation and knockdown confirmation. |
| Gi/o Signaling Pathway Detection | Compatible with cAMP HTRF and calcium flux assays using TarMart stable cell lines (full-length GPCR). |
Live CMKLR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CMKLR1 (ChemR23) therapeutics is intensifying, with the field shifting from traditional inflammation models to immuno-oncology and metabolic disease modulation. As a key GPCR controlling dendritic cell, macrophage, and adipocyte biology, CMKLR1 represents a high-value entry point for modulating the tumor microenvironment (TME) and resolving chronic inflammation. First-generation small-molecule antagonists (e.g., from Chemocentryx, BMS) face selectivity challenges against the related receptor GPR1. The next wave of R&D is targeting biased agonism (selective activation of Gαi vs β-arrestin), allosteric modulation, and peripheral-restricted antagonism to maximize therapeutic index. Simultaneously, metabolism-focused programs (e.g., NGM Biopharmaceuticals) are exploring agonists for obesity and type 2 diabetes, leveraging the chemerin-CMKLR1 axis in adipose tissue remodeling and beige fat activation. The convergence of immuno-oncology and metabolic disease indications drives demand for species-cross-reactive assay systems capable of supporting both inflammatory and metabolic phenotypic screens.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Chemocentryx, BMS, Lead Pharma | Rheumatoid Arthritis, Psoriasis, NASH, Obesity | Selectivity vs GPR1 (Need CMKLR1/GPR1 dual cell lines); Calcium Flux & Beta-Arrestin Recruitment (Stable Cell Line with Native Conformation) |
| Monoclonal Antibody | Novartis, Immunometabolic Biotechs | Solid Tumors (TME reprogramming), Metabolic Syndrome | Flow Cytometry Binding (Need Native Conformation Cells); Internalization assays (High-purity anti-CMKLR1 antibodies) |
| Peptide Agonist | Academic Labs, Biotech Startups | Inflammation Resolution, Inflammatory Bowel Disease | Ligand Displacement (Need Chemerin/RARRES2 protein controls); Competitive binding assays |
| Biased Ligand / Allosteric Modulator | Early Discovery Programs | Metabolic Syndrome, Fibrosis | Pathway Selectivity Panel (Need ortholog and mutant counter-screens); cAMP vs β-arrestin bias detection |
Conclusion
TarMart provides an integrated solution for CMKLR1 drug discovery: full-length GPCR lentivirus and stable cell lines for native conformation, sequence-verified ligands and related receptors (GPR1, CCRL2, FPR2) for selectivity profiling, and benchmark antibodies and siRNA sets for assay validation. This ecosystem supports the full pipeline from HTS to preclinical characterization, empowering researchers to advance best-in-class CMKLR1 modulators.